Products

PharmaEssentia has developed a novel technology platform designed to realize the therapeutic potential of interferons for treating various cancers, including myeloproliferative neoplasms (MPNs).

Our Taiwan-based R&D Center brings together teams specializing in research chemistry, analytical science, cell culture and engineering, pharmaceutical science, and process development, enabling PharmaEssentia to control the development of therapies from initial discovery to preparing them for commercial production.

All of our drug substance production and chemistry, manufacturing, and control (CMC) is conducted in PharmaEssentia’s state-of-the-art, FDA-compliant facilities.